Sanofi-Aventis’ Ambien about to get generic competition. But, some good news on the Lovenox front.
Pfizer gets a major slap for old Pharmacia marketing practices with Genotropin.
Glaxo gets an approval for Veramyst (allergy treatment).
WSJ Health blog speculates “who’s next?“, after MedImmune sale to AstraZeneca.
Novartis reports strong Q1 financial results.
Merck’s Arcoxia goes down for the FDA count.
Leave a Reply